Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[4] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.[5]
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[6] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[6]
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[7]
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.[8][9]
See also
External links
References
- U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc. U.S. Securities and Exchange Commission, retrieved July 31, 2023^
- Amphastar Pharmaceuticals Inc Bloomberg, retrieved 2024-03-19^
- Amphastar Pharmaceuticals, Inc. (AMPH) Income Statement - Yahoo Finance finance.yahoo.com, retrieved 2024-03-19^
- Amphastar Pharmaceuticals, Inc. (AMPH) NASDAQ.com, NASDAQ OMX Group, retrieved 3 January 2016^
- Profile:Amphastar Pharmaceuticals Inc (AMPH.O) Reuters^
- Arif Arsalan. After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version Endpoints, February 21, 2017^
- Nate Raymond. Momenta, Amphastar settle generic Lovenox drug patent case Reuters, June 19, 2019, retrieved March 14, 2024^
- Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash Yahoo Finance, 24 April 2023, retrieved 2023-04-26^
- Amphastar buys Baqsimi to build out specialty med offering www.thepharmaletter.com, retrieved 2023-04-26^